Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk

被引:23
|
作者
Skibola, CF
Bracci, PM
Paynter, RA
Forrest, MS
Agana, L
Woodage, T
Guegler, K
Smith, MT
Holly, EA
机构
[1] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[3] Appl Biosyst Inc, Adv Res & Technol, Foster City, CA USA
关键词
D O I
10.1158/1055-9965.EPI-05-0343
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Expression of prolactin and of prolactin and estrogen receptors in lymphocytes, bone marrow, and lymphoma cell lines suggests that hormonal modulation may influence lymphoma risk. Prolactin and estrogen promote the proliferation and survival of B cells, factors that may increase non-Hodgkin lymphoma risk, and effects of estrogen may be modified by catechol-O-methyltransferase (COMT), an enzyme that alters estrogenic activity. Cytochrome P450 17A1 (CYP17A1), a key enzyme in estrogen biosynthesis, has been associated with increased cancer risk and may affect lymphoma susceptibility. We studied the polymorphisms prolactin (PRL) -11496>T, CYP17A1 -34T>C, and COMT 108/158Val>Met, and predicted haplotypes among a subset of participants (n = 308 cases, n = 684 controls) in a San Francisco Bay Area population-based non-Hodgkin lymphoma study (n = 1,593 cases, n = 2,515 controls) conducted from 1988 to 1995. Oral contraceptive and other hormone use also was analyzed. Odds ratios (OR) for non-Hodgkin lymphoma and follicular lymphoma were reduced for carriers of the PRL -1149TT genotype [OR, 0.64; 95% confidence interval (95% CI), 0.41-1.0; OR, 0.53; 95% CI, 0.26-1.0, respectively]. Diffuse large-cell lymphoma risk was increased for those with CYP17A1 polymorphisms including CYP17A1 -34CC (OR, 2.0; 95% CI, 1.1-3.5). ORs for all non-Hodgkin lymphoma and follicular lymphoma among women were decreased for COMT IVS1 701A>G [rs737865; variant allele: OR, 0.53; 95% CI, 0.34-0.82; OR, 0.42; 95% CI, 0.23-0.78, respectively]. Compared with never users of oral contraceptives, a 35% reduced risk was observed among oral contraceptive users in the total population. Reduced ORs for all non-Hodgkin lymphoma were observed with use of exogenous estrogens among genotyped women although 95% CIs included unity. These results suggest that PRL, CYP17A1, and COMT may be relevant genetic loci for non-Hodgkin lymphoma and indicate a possible role for prolactin and estrogen in lymphoma pathogenesis.
引用
收藏
页码:2391 / 2401
页数:11
相关论文
共 47 条
  • [21] Genetic polymorphisms in glutathione S-transferases and cytochrome P450s, tobacco smoking, and risk of non-Hodgkin lymphoma
    Kilfoy, Briseis A.
    Zheng, Tongzhang
    Lan, Qing
    Han, Xuesong
    Qin, Qin
    Rothman, Nathaniel
    Holford, Theodore
    Zhang, Yawei
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (05) : 279 - 282
  • [22] Discovery of Novel Non-Steroidal Cytochrome P450 17A1 Inhibitors as Potential Prostate Cancer Agents
    Wrobel, Tomasz M.
    Rogova, Oksana
    Andersen, Kasper L.
    Yadav, Rahul
    Brixius-Anderko, Simone
    Scott, Emily E.
    Olsen, Lars
    Jorgensen, Flemming Steen
    Bjorkling, Fredrik
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (14) : 1 - 12
  • [23] Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors
    Bonomo, Silvia
    Hansen, Cecilie H.
    Petrunak, Elyse M.
    Scott, Emily E.
    Styrishave, Bjarne
    Jorgensen, Flemming Steen
    Olsen, Lars
    SCIENTIFIC REPORTS, 2016, 6
  • [24] Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population
    Neslihan Kocabaş
    Semra Şardaş
    Suzanne Cholerton
    Ann K. Daly
    Ali Karakaya
    Archives of Toxicology, 2002, 76 : 643 - 649
  • [25] Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors
    Silvia Bonomo
    Cecilie H. Hansen
    Elyse M. Petrunak
    Emily E. Scott
    Bjarne Styrishave
    Flemming Steen Jørgensen
    Lars Olsen
    Scientific Reports, 6
  • [26] Interactions between genetic polymorphism of cytochrome P450-1B1, sulfotransferase 1A1, catechol-o-methyltransferase and tobacco exposure in breast cancer risk
    Saintot, M
    Malaveille, C
    Hautefeuille, A
    Gerber, M
    INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (04) : 652 - 657
  • [27] Multistep Binding of the Non-Steroidal Inhibitors Orteronel and Seviteronel to Human Cytochrome P450 17A1 and Relevance to Inhibition of Enzyme Activity
    Child, Stella A.
    Guengerich, F. Peter
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (12) : 6513 - 6522
  • [28] Cytochrome P450CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population
    Kocabas, NA
    Sardas, S
    Cholerton, S
    Daly, AK
    Karakaya, AE
    ARCHIVES OF TOXICOLOGY, 2002, 76 (11) : 643 - 649
  • [29] Polymorphisms of Cytochrome P450 1A2 and N-acetyltransferase Genes, Meat Consumption, and Risk of Colorectal Cancer
    Yeh, Chih-Ching
    Sung, Fung-Chang
    Tang, Reiping
    Chang-Chieh, Chung Rong
    Hsieh, Ling-Ling
    DISEASES OF THE COLON & RECTUM, 2009, 52 (01) : 104 - 111
  • [30] Polymorphisms in Th1/Th2 cytokine genes, hormone replacement therapy, and risk of non-Hodgkin lymphoma
    Zhu, Gongjian
    Pan, Dongsheng
    Zheng, Tongzhang
    Lan, Qing
    Chen, Xuezhong
    Chen, Yingtai
    Kim, Christopher
    Bi, Xiaofeng
    Holford, Theodore
    Boyle, Peter
    Leaderer, Brian
    Chanock, Stephen J.
    Rothman, Nathaniel
    Zhang, Yawei
    FRONTIERS IN ONCOLOGY, 2011, 1